[1] Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin MicrobiloI Rev, 2002; 15, 716-46. doi:  10.1128/CMR.15.4.716-746.2002
[2] Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Ch, 2003; 47, 1958-62. doi:  10.1128/AAC.47.6.1958-1962.2003
[3] Heidarieh P, Mirsaeidi M, Hashemzadeh M, et al. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran. Microb Drug Resist, 2016; 22, 172-8. doi:  10.1089/mdr.2015.0134
[4] Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemot, 1999; 44, 393-5. doi:  10.1093/jac/44.3.393
[5] Swenson JM, Wallace RJ Jr, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Ch, 1985; 28, 807-11. doi:  10.1128/AAC.28.6.807
[6] Santos A, Cremades R, Rodriguez JC, et al. Activity of various drugs alone or in combination against Mycobacterium fortuitum. J Infect Chemother, 2010; 16, 64-7. doi:  10.1007/s10156-009-0008-1
[7] Gole GV, Set R, Khan N, et al. Drug susceptibility testing of rapidly growing mycobacteria in extrapulmonary tuberculosis. Indian J Tuberc, 2016; 63, 119-22. doi:  10.1016/j.ijtb.2016.04.001
[8] Santos DR, Lourenco MC, Coelho FS, et al. Resistance profile of strains of Mycobacterium fortuitum isolated from clinical specimens. J Bras Pneumol, 2016; 42, 299-301. doi:  10.1590/s1806-37562016000000073
[9] Cao B, Qu JX, Yin YD, et al. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J, 2015; DOI: 10. 1111/crj. 12379.
[10] Bercovier H, Kafri O, Sela S. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun, 1986; 136, 1136-41. doi:  10.1016/0006-291X(86)90452-3